ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neurological Biomarkers
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1598434
Metabolic Syndrome is Associated with Prognosis in Patients with Acute Ischemic Stroke After Intravenous Thrombolysis: A Prospective Cohort Study
Provisionally accepted
- 1Third Hospital of Shanxi Medical College, Taiyuan, Shanxi Province, China
- 2Linfen People's Hospital, Linfen, Shanxi Province, China
- 3Beijing Yanhua Hospital, Yanshan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Metabolic syndrome (MetS) is a known risk factor for stroke, but its impact on prognosis after intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) remains unclear. This study aimed to evaluate the association between MetS and prognosis in AIS patients treated with IVT.We conducted a prospective cohort study including AIS patients who received IVT at Shanxi Bethune Hospital between January 2022 and December 2023.Propensity score matching (PSM) was applied to balance baseline characteristics between MetS and non-MetS groups. The primary outcome was 3-month all-cause mortality. Secondary outcomes included good functional outcome (modified Rankin Scale [mRS] 0-2) and symptomatic intracranial hemorrhage (SICH).Results: After PSM, 292 patients (146 pairs) were enrolled in the analysis. The allcause mortality rate within 3 months was significantly higher in the MetS group compared to the non-MetS group (24.0% vs. 11.6%; p < 0.01). Multivariate Cox regression analysis indicated that MetS was independently associated with increased 3month mortality (adjusted hazard ratio [HR] = 2.50, 95% CI: 1.35-4.60; p < 0.01). A dose-response relationship was observed between the number of MetS components and mortality. Additionally, patients with MetS were less likely to achieve good functional outcomes (adjusted odds ratio [OR] = 0.47, 95% CI: 0.28-0.77; p < 0.01) and had a higher risk of SICH (adjusted OR = 2.40, 95% CI: 1.17-4.92; p = 0.02).MetS is an independent predictor of increased mortality, poorer functional recovery, and higher risk of SICH in AIS patients treated with IVT. Early identification and management of metabolic risk factors may improve outcomes in this population.
Keywords: Acute ischemic stroke, intravenous thrombolysis, prognosis, metabolic syndrome, Mortality
Received: 23 Mar 2025; Accepted: 02 Jun 2025.
Copyright: © 2025 Chen, Liu, Li and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaofang Zhang, Beijing Yanhua Hospital, Yanshan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.